Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus

Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus

Objective The management of systemic lupus erythematosus (SLE) flares can incur substantial healthcare costs. In the phase III BLISS-SC trial, subcutaneous (SC) belimumab 200 mg plus standard therapy was associated with significant reductions in time to severe flare, and risk of flares, versus place...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Christopher F Bell, Tasneem Lokhandwala, Binglin Yue, Anna D Coutinho
Formato: article
Lenguaje:EN
Publicado: BMJ Publishing Group 2021
Materias:
Immunologic diseases. Allergy
RC581-607
Acceso en línea:https://doaj.org/article/c9526a6e5db64288b6b403ecd95f6e63
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares